IRVINE, Calif., Dec. 20, 2010 /PRNewswire-FirstCall/ —
Endologix, Inc. (Nasdaq:
ELGX), developer of minimally invasive treatments for aortic
disorders, announced today that Guido Neels, Managing Director at
Essex Woodlands Health Ventures, has joined the Endologix Board of
Directors. Essex Woodlands was the majority shareholder of Nellix
Inc, which was acquired by Endologix in an all stock transaction on
December 13, 2010. In conjunction with the acquisition, Essex
Woodlands made a $15 million equity investment in Endologix.
Endologix now has five independent directors and three
non-independent directors.
Franklin D. Brown, Chairman of the Board, said, “I would like to
welcome Guido to the Endologix Board of Directors . He has
extensive experience in the medical device sector and will provide
valuable guidance as we work to expand the AAA market through the
introduction of innovative new products such as Nellix and Ventana.
We will also benefit from his experience leading the global
operations of Guidant, particularly as we expand our infrastructure
and build our direct sales force in Europe.”
Mr. Neels currently holds Board positions at ROX Medical, Inc.,
Entellus Medical, Oraya Therapeutics, Inc., Arsenal Medical and
EndGenitor Technologies. Prior to joining Essex Woodlands in 2006,
Mr. Neels served as Chief Operating Officer of Guidant Corporation,
a world leader in the development of cardiovascular medical
products. He was responsible for the global operations of Guidant’s
four operating units, Cardiac Rhythm Management, Vascular
Intervention, Cardiac Surgery, and Endovascular Solutions. He
previously served as Group Chairman, Office of the President at
Guidant, responsible for worldwide sales operations, corporate
communications, corporate marketing, investor relations and
government relations. Prior to joining Guidant, Mr. Neels held
various general management,
‘/>”/>
